Advertisement

Woburn-based biotech company BioVex Inc. today said that it has launched a Phase 3 study of its OncoVEXGM-CSF as a treatment for patients with locally advanced squamous cell carcinoma of the head and neck.

The study will be conducted at sites in the U.S. and U.K., and will enroll 528 previously untreated patients. The goal is to demonstrate a statistically significant increase in two-year, event-free survival for patients treated with chemoradition and with OncoVEXGM-CF.

SOURCE

Advertisement
Advertisement